

PRODUCT INFORMATION



Glepaglutide (acetate)

Item No. 41274

Synonym: ZP1848

Peptide Sequence: HGEGETFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH₂

MF: C₁₉₇H₃₂₅N₅₃O₅₅ • XC₂H₄O₂

FW: 4,316.1

Purity: ≥95%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years

H — His — Gly — Glu — Gly — Thr — Phe — Ser — Ser — Glu — Leu —

Ala — Thr — Ile — Leu — Asp — Ala — Leu — Ala — Ala — Arg —

Asp — Phe — Ile — Ala — Trp — Leu — Ile — Ala — Thr — Lys —

Ile — Thr — Asp — Lys — Lys — Lys — Lys — Lys — Lys — NH₂

• XCH₃CO₂H

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Glepaglutide (acetate) is supplied as a solid. Aqueous solutions of glepaglutide (acetate) can be prepared by directly dissolving the solid in aqueous buffers. Glepaglutide (acetate) is slightly soluble (0.1-1 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

Glepaglutide is a peptide agonist of the glucagon-like peptide 2 receptor (GLP-2R).¹ It selectively induces cAMP accumulation in HEK293 cells expressing GLP-2R over those expressing GLP-1R (EC₅₀s = 0.24 and 8.7 nM, respectively, for the human receptors). Glepaglutide (10 mg/kg per day for 26 weeks) increases mucosal hyperplasia thickness in the duodenum, jejunum, and ileum, as well as increases small intestinal wet weight and length, an effect that lasts six weeks post-administration, in rats.² It also increases small intestinal mass and length, as well as reduces ileal levels of α-1-acid glycoprotein (AGP 1) and myeloperoxidase (MPO), in a rat model of inflammatory bowel disease (IBD) induced by indomethacin (Item No. 70270) when administered at a dose of 400 nmol/kg twice per day.³

References

1. Hargrove, D.M., Alagarsamy, S., Croston, G., *et al.* Pharmacological characterization of apraglutide, a novel long-acting peptidic glucagon-like peptide-2 agonist, for the treatment of short bowel syndrome. *J. Pharmacol. Exp. Ther.* **373**(2), 193-203 (2020).
2. Glerup, P., Sonne, K., Berner-Hansen, M., *et al.* Short- versus long-term, gender and species differences in the intestinotrophic effects of long-acting glucagon-like peptide 2 analog. *Physiol. Res.* **71**(2), 323-326 (2022).
3. Skarbalienė, J., Mathiesen, J.M., Larsen, B.D., *et al.* Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats. *BMC Gastroenterol.* **23**(1), 79 (2023).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/29/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM